COYA 302, an injection therapy in development for the treatment of ALS, has been awarded fast track status by the U.S. Food and Drug Administration. The therapy aims to slow ALS progression by ...
The technology may help predict the way the unpredictable disease progresses in individual patients, Temple researchers say ...
About 5,000 people are diagnosed in the U.S. each year. Most ALS patients are given a life expectancy of two to five years ...
Whether tense or free, timid or morose, the avatar encapsulated all the long years of training Breanna Olson took to become a ...
Advocates pushing for an ALS cure took part in a mass Ice Bucket Challenge Saturday outside Yonkers Raceway at Empire City. In addition to raising awareness and money for research, the annual event ...
Misshapen proteins cause a mess of trouble—particularly in neurodegenerative diseases. But a new study suggests it's possible ...
Instead of scheduling many different appointments with different providers, patients like Welling can see all of their ...
Fast-track status is intended to speed the development and review of treatments for serious conditions with unmet medical needs. It will allow Spinogenix to have more frequent interactions with the ...
In this week's Biotech Scorecard newsletter, Adam Feuerstein takes on the company touting gold microdust suspended in water ...
San Anselmo author Mindy Uhrlaub carries a gene that can cause amyotrophic lateral sclerosis (ALS), also known as Lou ...
Tazbentetol is an investigational, once-daily synaptic regenerative therapy designed to restore cognitive and motor function in ALS.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results